title: Capitated chronic disease management programs: a new market for pharmaceutical companies.
abstract: With corporatism of the medical care delivery system, the pharmaceutical industry is searching for new ways to market prescription drug product lines. A new strategy focuses on developing chronic disease management programs. In doing so, pharmaceutical companies work with clinical leaders of HMOs or large physician groups on disease management guidelines to reduce practice pattern variations and improve the quality of patient care. In addition, pharmaceutical companies capitate payment to physicians treating chronic disease patients to give them financial incentives to comply with the disease management guidelines.
authors.affiliation: Express Scripts, Inc., St. Louis, MO, USA.
authors.forename: D G
authors.initials: DG
authors.lastname: Cave
mesh_terms: D002204:Capitation Fee; D002908:Chronic Disease / Q000188:drug therapy* / Q000191:economics*; D016000:Cluster Analysis; D015897:Comorbidity; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000191:economics; D003953:Diagnosis-Related Groups; D004345:Drug Industry / Q000191:economics*; D011307:Drug Prescriptions / Q000191:economics*; D006279:Health Maintenance Organizations / Q000191:economics / Q000592:standards; D006801:Humans; D009511:New England; D010347:Patient Care Planning / Q000191:economics* / Q000592:standards; D017410:Practice Guidelines as Topic; D014481:United States